Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of umbilical cord blood regenerated particle and composition thereof in treatment of cerebral degenerative diseases

A degenerative disease, umbilical cord blood technology, applied in the field of biomedicine, can solve complex and multi-step problems, and achieve the effect of alleviating brain decline and improving cognitive and behavioral functions

Inactive Publication Date: 2018-09-14
孔五一
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is a delicate, complex, multi-step process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of umbilical cord blood regenerated particle and composition thereof in treatment of cerebral degenerative diseases
  • Use of umbilical cord blood regenerated particle and composition thereof in treatment of cerebral degenerative diseases
  • Use of umbilical cord blood regenerated particle and composition thereof in treatment of cerebral degenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Preparation of umbilical cord blood regeneration particles

[0051] In this example, the preparation of umbilical cord blood regeneration particles is exemplified.

[0052]Blood source: The umbilical cord blood is collected into a blood bag containing anticoagulant. The anticoagulant is the original sodium citrate in the blood bag, and the umbilical cord blood is transported to Preparation lab.

[0053] Conditions: The process of obtaining umbilical cord blood regeneration particles requires a complete aseptic operation.

[0054] Specific steps are as follows:

[0055] (1) The umbilical cord blood was taken and centrifuged at 200g for 10 minutes. After centrifugation, it was divided into two parts, the upper layer solution A and the lower layer precipitate A.

[0056] (2) Take the lower layer of precipitate A, add PBS at a volume ratio of 1:2-5 for slight washing, and centrifuge at 200g for 10 minutes. After centrifugation, it is divided into two parts, the upper lay...

Embodiment 2

[0063] Regenerating particles migrate into the injured cerebral hemisphere in a ribbon pattern

[0064] The experimental group injected the regenerative particles (GFP marker) obtained in Example 1 into the mice with ischemic brain injury through the tail vein, and the control group injected normal saline.

[0065] At 7 days, the sections of the control group brains were all negative for GFP ( figure 2 A), but positive for GFP in the GFP antibody reactive fraction ( figure 2 B). At 4 weeks, consecutive sections of control part brains were negative for GFP ( figure 2 C), but positive for GFP in the GFP antibody reactive fraction ( figure 2 D). At 7 days, whole brain sections showed that almost all left hemisphere tissue was ischemic and damaged, and it was enhanced and enlarged. GFP-positive material showed a banded pattern (see figure 2 B) Arranged around the injured hemisphere.

Embodiment 3

[0067] Regenerating Particles Forming Granular Cells

[0068] The experimental group injected the regenerative particles (GFP marker) obtained in Example 1 into the mice with ischemic brain injury through the tail vein, and the control group injected normal saline.

[0069] After the regenerative particles migrate into the brain tissue, they first fuse into a non-nucleated cell-like structure, and then further form nucleated cells. High-magnification microscopic observation further confirmed that regenerative particles from capillaries (see Figure 4 ) fuse together before forming granule cells and further develop to form new granule cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses use of an umbilical cord blood regenerated particle and a composition thereof in treatment of cerebral degenerative diseases. The umbilical cord blood regenerated particle hasthe following characteristics that: the diameter size of the umbilical cord blood regenerated particle is 1-5micrometers; the umbilical cord blood regenerated particle contains trace DNA component; and the umbilical cord blood regenerated particle expresses Oct3 / 4, Nanog and Sox2 proteins. Research finds that the therapeutic agent prepared from the umbilical cord blood regenerated particle and thecomposition thereof can effectively treat cerebral degenerative diseases, and is especially suitable for regeneration of brain nerve cells and delaying of brain degeneration.

Description

technical field [0001] The present invention relates to the field of biomedicine, especially the fields of histocytology, regenerative medicine, and disease treatment, and especially relates to the application of umbilical cord blood regeneration particles and its composition in the treatment of brain degenerative diseases. Background technique [0002] Brain degenerative disease is a kind of disease that seriously endangers human health. It mainly causes the abnormal death and atrophy of specific neurons in the central nervous system of the brain, leading to serious defects in brain nerve function, cognitive or motor impairment, and this damage is irreversible. It worsens over time, eventually leading to brain dysfunction. [0003] Brain degenerative diseases include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), Pick's disease, senile depression, hand tremor and other brain atrophy (BA) etc. Among them, Alzheimer's...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0793C12N5/0797A61K35/51A61P25/00A61P25/28A61P25/16A61P25/24
CPCA61K35/51A61P25/00A61P25/16A61P25/24A61P25/28C12N5/0619C12N5/0623C12N2506/11
Inventor 孔五一
Owner 孔五一
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com